industry is plan COVID with we as program. contract headwinds our States five-year our well population deceleration believe experience DARPA, rapid did which under consistent a testing year, leading generation, products. platform overall growth in partnerships have United and as testing line the NIH, fourth microfluidics RADx levels initiatives vaccination our Thank CyTOF macro afternoon. that revenues, related Peter, we completed of milestones with We business outlined and and services decreased. several We quarter our notable pipeline. Mount to the our Vision the Sinai increased In with has the innovative XXXX. second base growth mass made in call good We we Earlier trends non-COVID the key launch from XXXX revenue and as this cytometry you, in in significant continued and rebound levels our including advanced our top strides R&D of
three into are objectives corporate organized innovation, beachheads of pillars which this is partnerships. XXXX Our growth, tied and to plan,
During of objectives towards generation the We advance in detail care minutes. the our QX objective and provide plan next believe, to decision-making. progress of in made this that will power we achieve in track each to XXXX health more I as categories a we on these we few remain on
Now to that speaking with We with we of in recovery improvement some major the period. improvement navigate operations market Japan activity over uneven levels below as we lab the QX and geographies continuing see markets slowest briefly an shifting the serve. successive across among dynamics waves for various countries serve we pre-COVID remain outbreaks. the Globally marginal individual estimate
of supply uncertainty status moderate We are as challenges, closely headwinds. regional and monitoring operational continue the which as restrictions which create further well chain introduces the travel variant, delta to
However, upon half are of based our the improving business the optimistic we demand on second today, as for particularly we we about what signals. year see balance base know
gears, key support we of our we'll As guidance increased for during outlook achievements the on I an testing provide five-year discuss COVID revenue recent quarter maintaining perspective later, year our our base strategy. business reduced business Shifting guidance and have these prior our full overview period will full-year while and add highlights range. how revenue
our vision beachheads, franchise. will partnerships. growth of execution them I context mentioned, for strategic innovation, break I calls down in each drivers; As distinct of the three
in this product suspension These recovery operating demand Let below project this labs higher and a speaking, demand Broadly consumables mass see significant general start mass still across business applications. conditions our with support that cytometry family. me market imaging and our to cytometry work. activity. solid we and includes pre-COVID their increased for backlogs many levels, steady Though suggest customer customers anecdotes are anticipate foreshadow for are there
underpin our months, few consumables. and sales These monthly plus orders momentum In for releases new fact expectations over growth signs mass balance full purchase seen our new our encouraging established the product records last year cytometry forming new we XXXX. have for with the of
the the boosted suspension for and deliveries in goals and unit second we our opportunity are will attendance working cytometry mass supporting virtual our with half end including pleased strong service the this QX, of for training XXXX, fourth environmental to effort, macro Turning and the And event as several XT ongoing of system for execution launch up given capacity engineers, market first exceeding the our us. well XT. we instrument as needs, anticipate versus And a a was we CyTOF field be beyond. awareness scale business, we and registration a market to was plan, are manufacturing new The which reaction interest. XXX% we suspension Internally, our May, analyzers for of in constraints. more The with starting at believe, very CyTOF to potential QX. with digital innovation, generation CyTOF in launched accommodate and the what May created hundred demand
automation compact sample For those did automated events, loading, more to reduce an XT launch our a built-in system to uptime, investor room of requests periodic not modification. higher of the chiller you and CyTOF user who that cleaning sample a noise, less attend requires May events, system addresses approach for greater clogging footprint product or
With over these price improved in available system. cycle. costs for deploy prior generation The ownership our operational capabilities, with XTs, lower projected to space new of most can Helios instrument two the lower one a system five-to-seven-year and customers allocated is also
launch, that translational trade-in, one As to QX. options. of and during revenue to These that total in perform clinical commercial primarily these we've first increasing year-to-date, seven trade-up customer pleased accommodate the orders instruments, research. leasing to weeks and sold well ordered offer and or exclusively CRO system order. two of biopharma represents Among accounts deliveries demand, our three we were XTs, as the seven systems new report including attractive first eight also for I'm two
New customers accounted for two of these orders.
XXXX, penetration are translational signals, of as pleased these protein our imaging demand. our the current the provide standard research of the of system again increasing growing consumables as expect backlogs release our streams revenue we of platform. ahead, market unit expand and with installed years existing Customers well resolution, as reported These We And given the similar for in with imaging market seek remains this future signaling the are product a revenue sales that In dynamics. gold growth imaging contribute further are new studies, to while upgrades base. single-cell have growth to in placements for in generation, In we higher generation of early pull-through will cytometry high-plex fourth Instruments potential and mix shadow to the new will recurring tissue. that our enable seeing for customers. to we mass our placements consumables services, a we Hyperion
position competitive, our carefully but solution platform are research platform. we changes serve leadership. monitoring to behaviors, increasingly in planned our on we market the the clinical for our believe, release updates We in translational as timelines believe customer positioned our a will needs. imaging is and us market market We second-generation We to maintain put best remains know strong buying next-generation development
content deliver Assay, our will MDIPA, Immune or vaccine immuno-oncology for we studies. and enhancements additional introducing QX, Lastly, in Direct Maxpar antibody award-winning Profiling to
conjugation are we that which and we planning a addition, In isotopes to Maxpar-On-Demand, pilot, features antibodies. program, of pre-curated combinations antibody introduce call
we see are decision-making, we the tools In MDIPA exposure orders that Our adoption used from influence May investor growth. launch. these cytometry to innovation beachheads, underpenetrated milestones, in in including of care $X increase will our to segments more particular, organizations. customers, achieved we for XXX event has who market including as Transitioning number and than we mass in notable product attractive revenue, working for future opportunities are since million in believe, to outlined CROs health a serve where the our we
CROs We on customers, engagements collaboration sector. development most imaging. CRO more contract with biopharma than focuses increasing their discovery are which to the the agreement a drug as in customer a drug advancing system. high-resolution Hyperion markets We new development of neurosciences leading and capabilities focusing ImaBiotech pleased such imaging the service objectives. in to pharma our ImaBiotech, high system oncology announce are and XXX and and explore interest with customers biotech CRO the hope accelerate has utilizing on in purchased serve to ImaBiotech flexity,
health our side addition, a business, specialized our needs CRO added we the to of segment. In community important of suspension on serve to this the surging care vaccine
increased system conclusion, our be their imaging CRO platforms path suspension geographic expansion. beachheads. CRO will partner believe and ordered adoption Another to network by of support of we the our influenced that In a growing to biopharma
our in bringing on beachheads of total broadly, focus users number incorporated clinical Our translational XXX. QX, seven cytometry trials new more the to studies. In technology networks in our both, was is the terms increasing results clinical and CRO total of and mass executing yielding
been technology related featured of with imaging publications than X,XXX our to platform. in Hyperion Our more XXX them has nearly
turn me partnerships. to Let
agreement, Ultivue, in we solutions. In addition co-marketing ImaBiotech the medicine with agreement advancing announced precision to a a leader
on expanding the are available analysis, development biomarker efforts tissue and researchers. portfolio of to marketing for Our drug tools focused discovery
to access will Via serve this business each Insights offer to approaches of company these plan technologies these technologies. to field. complementary Our combined Services are fast-growing increasing Therapeutic new customers market awareness and capabilities, our we
note, side we biopharma projects a As latest during for reporting period. the accounts completed XX
We analysis cytometry. also a microfluidics on to imaging customers to enable software co-development established and focused agreement Switching images automated recently package analysis their mass our and a our reading of images. collaboration Visiopharm automate to upload into signed more management and now business. the data of with We
base been growth. Our steadily delivering revenue renewed microfluidics and business recovering has
We our beyond account growth are innovation, formula and of new on opportunities executing testing are partners. seeing COVID-related and beachheads
opening efficacy forecasting decline testing regarding demand expected and overall in comments, in QX presents vaccine that faster performance than my in mentioned As our missed we testing area. and did revenue The targets future we challenges. COVID-related uncertainty
durable the however, foundational testing. generated investments NIH from Rather such the is has strategy not predicated strategy, on large Defense. elements success and in Our in of COVID a to COVID Vision been our vision Department leveraging agencies the the of as revenue and XXXX invest diagnostic --
manufacturing the foundational by pleased our upgrade, these We on are including of progress NIH funded elements, facility approaching our the RADx with contract. end
our for year growth diagnostic the will benefits of Over than state-of-the-art a installing range years come. COVID which on capacity we lines, broad novel of have equipment new a for Biomark demanding XXX a Other to pieces a new well new, manufacturing suited of last our schedule configuration, tripled more platform, applications. with included response support chip
and development franchise. Biomark call. to innovation internal our in May the of launch with respect milestones now achieved this next-generation significant Turning platform during we introduced to We
we numerous IFC milestone FDA for a review, are addition, adapted new In to fast to submit a approaching chip our that applications. sample-to-answer be can
a of the the system, large advanced a integrates interface Biomark easy-to-use Juno hybridize As instruments, with single our that size an and current will next-gen approach to two instruments novel a interface. HD our platform reminder, user one-sixth with into the Biomark touchscreen PCR,
diagnostic and intend encompass will industry go-to-market capabilities our fact, participants, XXX% at to In simplifying Though offering the microfluidics our new Biomark have OEM vision projected HD these to platforms to these lower market expectations complex balance of with instrument begun business for revenue vast total who the value. goal of Juno the We revenue of features the ultimately relationships. on new tremendous and coming we recruit our XXXX workflows platforms and with improvements ownership demo the base cost structure of to cost, modest, a of share existing are associated partners combined, majority testing. the proprietary new chips, reducing the of existing our our from
I'd share as many We new will come can we Biomark our developer highlight are to innovation. forms. more the entertaining is business like approach interest details Innovation One launch early we area and in service now.
meeting commitment quarterly during needs. and driving we operating customer a revenue QX, Our to the We record, service are a in offering line service new lines. the service part growing delivered of our new first to service environment. year, as multiyear team our PRO of face the continues to revenue brand pipeline innovation launched challenging of sustained a execute value driving extensions capabilities installed service half enhance service growth And the our In enhanced new base. and of we of Fluidigm
Olink let franchise. scale-up from transitioning our with in anticipate me In we Proteomics Now the of our development and QX, to commercialization partnerships phase phase. to microfluidics the turn contract
important the grateful market partner. serve exciting and for are opportunity We this to
response We We as are improvement in the ahead. in are events to prospects a partner and new product our excited cytometry our over the field its of by achieved weeks major summary, pleased growing launch In to business of financial a base of call Vision QX years results. for QXXX In milestone, partnership to our launched markets both second quarter conceptually ahead. penetrate the analysis. microfluidics Vikram advance is the protein is in detailed about the which the our more we steadily Biomark. forward of application-specific in introductions our and market Olink business. against and our the proteomics early their strategy a early to biomarker system product, I'll XXXX derivative an next-gen continued end designated with to mass the for new benchtop the response look turn QXXX and market now execution Vikram? learning our signature discussion
